These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 22742941)

  • 1. Current challenges with control of multi-drug resistant TB in Peru: Lessons from the past and goals for the future.
    Accinelli RA; Choi S
    Respirology; 2024 Aug; 29(8):662-664. PubMed ID: 38857974
    [No Abstract]   [Full Text] [Related]  

  • 2. Is it the time for abandoning longer regimens for drug-resistant tuberculosis.
    Singla R; Gupta A
    Indian J Tuberc; 2024; 71 Suppl 1():S3-S4. PubMed ID: 39067952
    [No Abstract]   [Full Text] [Related]  

  • 3. A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis.
    Cohen DB; Meghji J; Squire SB
    Int J Tuberc Lung Dis; 2018 Oct; 22(10):1127-1134. PubMed ID: 30236179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-sectional study of tuberculosis drug resistance among previously treated patients in a tertiary hospital in Accra, Ghana: public health implications of standardized regimens.
    Forson A; Kwara A; Kudzawu S; Omari M; Otu J; Gehre F; de Jong B; Antonio M
    BMC Infect Dis; 2018 Apr; 18(1):149. PubMed ID: 29606091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study.
    Acuña-Villaorduña C; Ayakaka I; Dryden-Peterson S; Nakubulwa S; Worodria W; Reilly N; Hosford J; Fennelly KP; Okwera A; Jones-López EC
    Am J Trop Med Hyg; 2015 Jul; 93(1):73-5. PubMed ID: 25940196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of drug-susceptibility testing for management of drug-resistant tuberculosis, Thailand, 2004-2008.
    Lam E; Nateniyom S; Whitehead S; Anuwatnonthakate A; Monkongdee P; Kanphukiew A; Inyaphong J; Sitti W; Chiengsorn N; Moolphate S; Kavinum S; Suriyon N; Limsomboon P; Danyutapolchai J; Sinthuwattanawibool C; Podewils LJ
    Emerg Infect Dis; 2014 Mar; 20(3):400-8. PubMed ID: 24565738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of tuberculosis].
    Eier A; Grass S
    Wien Med Wochenschr; 1994; 144(8-9):186-8. PubMed ID: 7941607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug resistant tuberculosis].
    Zwolska Z; Augustynowicz-Kopeć E
    Pol Merkur Lekarski; 2011 May; 30(179):362-6. PubMed ID: 21675144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
    Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area.
    Schreiber YS; Herrera AF; Wilson D; Wallengren K; Draper R; Muller J; Dawood H; Doucette S; Cameron DW; Alvarez GG
    Int J Tuberc Lung Dis; 2009 Oct; 13(10):1274-80. PubMed ID: 19793433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis treatment: dangerous regimens?
    Rieder HL; Arnadottir T; Trébucq A; Enarson DA
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
    [No Abstract]   [Full Text] [Related]  

  • 13. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru.
    Chavez Pachas AM; Blank R; Smith Fawzi MC; Bayona J; Becerra MC; Mitnick CD
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):52-8. PubMed ID: 14974746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru.
    Ponce M; Ugarte-Gil C; Zamudio C; Krapp F; Gotuzzo E; Seas C
    Trans R Soc Trop Med Hyg; 2012 Aug; 106(8):508-10. PubMed ID: 22742941
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.